Atlas Trials

Clinical Study on the Safety and Efficacy of Autologous CD84 Chimeric Antigen Receptor T-Cell Therapy for Adult Relapsed/Refractory Acute Myeloid Leukemia.

Clinical trial NCT06786299 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06786299
Sponsor
First Affiliated Hospital of Zhejiang University
Status
NOT_YET_RECRUITING
Phase
Early Phase 1
Study type
INTERVENTIONAL
Relapsed/Refractory Acute Myeloid Leukemia(AML)
Start date
2025-02-10
Primary completion
2026-10-31
Enrollment
18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.